<DOC>
	<DOCNO>NCT02334748</DOCNO>
	<brief_summary>The objective extension protocol collect safety data ( serious non-serious adverse event ) provide continuous canakinumab patient France complete study CACZ885G2301E1 , CACZ885G2306 CACZ885N2301 decision regard reimbursement France effective canakinumab ( Ilaris® ) indication .</brief_summary>
	<brief_title>A Study Canakinumab Patients With Systemic Juvenile Idiopathic Arthritis Hereditary Periodic Fevers Who Participated CACZ885G2301E1 , CACZ885G2306 CACZ885N2301 Studies</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Familial Mediterranean Fever</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Hereditary Autoinflammatory Diseases</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Criteria applicable patient Systemic Juvenil Idiopathic Arthritis SJIA ) : Patients complete international study CACZ885G2301E1 CACZ885G2306 without significant safety issue accord Investigator 's opinion . Patients complete international CACZ885G2306 study successfully withdraw canakinumab treatment per protocol disease relapse within one year withdrawal allow participate CACZ885GFR01 study . Criteria applicable patient HPF ( TRAPS , HIDS , crFMF ) : Patients complete international CACZ885N2301 study without significant safety issue accord Investigator 's opinion . Criteria applicable patient : Parent 's legal guardian 's write informed consent child 's assent , appropriate , patient 's write informed consent patient ≥ 18 year age must obtain study related activity assessment perform . History recur infection Hypersensitivity active substance excipients protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>